NCT05895825View on ClinicalTrials.gov

A Study of EOC237 in Patients With Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

September 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

EOC237

EOC237 for orally

Trial Locations (1)

100029

RECRUITING

National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd

INDUSTRY